33% of all health plans and employers cover GLP-1s for obesity; 67% of large employers do.
Structured coverage with clinical criteria, step therapy, lifestyle requirements, and quantity limits is how mid-market employers manage the risk.
Government markets are split. The BALANCE Model expands Medicare and Medicaid coverage in 2026-2027 while Medi-Cal eliminated it on January 1, 2026.
Finalize your 2027 PBM strategy by September 1 to leave runway for modeling and implementation.
The Numbers Have Changed. Your Decision Hasn't Gotten Easier.
According to Statista and Gallup, 12.4% of U.S. adults reported taking a GLP-1 for weight loss by mid-2025. That's up from 5.8% in February 2024. In less than two years, usage more than doubled.
Your employees are asking. Some are already paying out of pocket. And you're sitting down to build your 2027 formulary without a clean answer.
Here's what matters before you decide.
Who's Covering GLP-1s Right Now
The employer market is split. A July 2024 survey by the Pharmaceutical Strategies Group found only 33% of health plans and employers covered GLP-1s for obesity. Another 19% were considering it.
But large employers are moving faster. The Business Group on Health surveyed 125 large businesses representing 17.1 million employees. Sixty-seven percent were already covering GLP-1s for obesity treatment.
Size matters here. Larger employers can spread the risk. At 100 to 500 employees, you can't absorb an uncapped GLP-1 benefit without feeling it immediately. We've walked through the spend math in how GLP-1s are now a quarter of some plans' pharmacy spend.
The Peterson Health Technology Institute estimates nearly 58 million commercially insured adults are eligible for GLP-1s based on obesity criteria alone. That's the number that should keep you up at night if you're considering broad, unrestricted coverage.
The Four Levers You Can Actually Pull
You don't have to choose between full coverage and exclusion. Most mid-market employers are building structured coverage with controls. Here's how those controls work.
1. Clinical criteria
Require a BMI of 30 or above, or 27 with a documented comorbidity like type 2 diabetes or hypertension. This alone screens out casual use.
2. Step therapy
Require documented failure of lower-cost interventions before approving a GLP-1. That means a 90-day trial of a structured diet program or documented physician-supervised weight loss attempt first.
3. Lifestyle program requirement
Tie ongoing coverage to active enrollment in a qualifying nutrition or behavioral health program. Some employers are requiring quarterly check-ins to maintain eligibility.
Before you keep reading
Get the next one in your inbox.
Analysis like this, every other Wednesday. Written for the person who signs the renewal.
Subscribe and get the PBM Renegotiation Checklist. Free PDF.
Every other Wednesday. Unsubscribe anytime.
4. Quantity and duration limits
Cap the covered supply, or require re-authorization every six months with documented progress. Progress thresholds of 5% body weight loss by month six are common benchmarks.
Monthly retail prices for GLP-1 medications range from a few hundred dollars to more than $1,300 depending on the drug and formulation. One wrong step in the design and your utilization may soar. The bigger picture, where peptides reshape pharmacy spend long term, is in The Peptide Decade Just Started.
What's Changing in the Government Markets That Affects You
The policy environment is shifting fast. The BALANCE Model expands GLP-1 coverage for obesity under Medicare starting in 2027 and under Medicaid starting in 2026, according to KFF. Only 13 states currently cover GLP-1s for obesity under Medicaid, so that expansion is significant.
California went the other direction. Medi-Cal eliminated GLP-1 coverage for weight loss effective January 1, 2026, canceling all previously approved prior authorizations as of December 31, 2025.
What does this mean for your plan? Employees who lose public coverage will look to your plan next. If you're in an expansion state, expect increased enrollment pressure from spouses or dependents aging off Medicaid coverage.
On the administrative side, CMS-0057-F requires Medicare Advantage, Medicaid, CHIP, and ACA Exchange plans to implement FHIR-based prior authorization APIs by January 1, 2027. The rule doesn't directly bind ERISA self-funded plans, but most PBMs serve both books and will roll the same plumbing out commercially. If your TPA or PBM isn't ready, your clinical criteria controls won't function the way you designed them.
Build the Decision Around Total Cost, Not Just Drug Cost
There are two (financial) questions here. One: what does a GLP-1 cost over 3-5-10 years? And two: what does unmanaged obesity cost your plan over that same 3-5-10 years in downstream claims? Comorbidity spend, musculoskeletal claims, sleep apnea, cardiovascular events.
Pull your claims. Look at your population's BMI distribution if you have it through a health risk assessment. Model two scenarios: structured GLP-1 coverage with clinical controls versus continued exclusion with no intervention.
The second scenario isn't free. Structured coverage with step therapy, lifestyle requirements, and progress thresholds isn't a benefit expansion. It's a managed clinical program. Design it that way, price it that way, and communicate it that way.
Your 2027 PBM choice (assuming 1/1 plan year) will need to be finalized by September 1 for a reasonable implementation. That's not much runway to model this correctly. Start the conversation with your advisor, PBM and stop-loss carrier now.
Frequently Asked Questions
Should we cover GLP-1s in our 2027 formulary?
Most mid-market employers shouldn't choose between full coverage and exclusion. The defensible position is structured coverage with clinical criteria, step therapy, lifestyle program requirements, and quantity limits. That converts an open-ended drug benefit into a managed clinical program.
What BMI threshold should we use for GLP-1 coverage?
The clinical standard is a BMI of 30 or above, or a BMI of 27 with a documented comorbidity like type 2 diabetes, hypertension, or sleep apnea. That aligns with FDA labeling and screens out casual use.
Does CMS-0057-F apply to our self-funded plan?
Not directly. CMS-0057-F binds Medicare Advantage, Medicaid managed care, CHIP managed care, and ACA Exchange plans. ERISA self-funded plans aren't covered. But most PBMs run both books, so the FHIR prior authorization plumbing will arrive on the commercial side too.
How much do GLP-1s cost employer plans?
Monthly retail prices range from a few hundred dollars to more than $1,300 depending on the drug and formulation. Some plans now report GLP-1s consume a quarter of total pharmacy spend.
When do we need to finalize our 2027 GLP-1 strategy?
If you're on a January 1 plan year, your 2027 PBM and formulary decisions need to be finalized by September 1, 2026. That's the minimum runway for stop-loss underwriting, member communications, and clinical criteria configuration.
